Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark S Lee

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Immunity|November 22, 2018
Bonds Voyage! A Dissociative Model of TCR-CD3 Triggering Is ProposedKatrina Lichauco, Mark S Lee, Michael S Kuhns
Cell Reports|February 2, 2018
Reciprocal TCR-CD3 and CD4 Engagement of a Nucleating pMHCII Stabilizes a Functional Receptor MacrocomplexCaleb R Glassman, Heather L Parrish, Mark S Lee, et al.
Elife|July 21, 2022
Enhancing and inhibitory motifs regulate CD4 activityMark S Lee, Peter J Tuohy, Caleb Y Kim, et al.
Biorxiv : the Preprint Server for Biology|May 22, 2023
The CD4 transmembrane GGXXG and juxtamembrane (C/F)CV+C motifs mediate pMHCII-specific signaling independently of CD4-LCK interactionsMark S Lee, Peter J Tuohy, Caleb Y Kim, et al.
Elife|April 19, 2024
The CD4 transmembrane GGXXG and juxtamembrane (C/F)CV+C motifs mediate pMHCII-specific signaling independently of CD4-LCK interactionsMark S Lee, Peter J Tuohy, Caleb Y Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2020
A biomimetic five-module chimeric antigen receptor (<sup>5M</sup>CAR) designed to target and eliminate antigen-specific T cellsShio Kobayashi, Martin A Thelin, Heather L Parrish, et al.
Clinical Pharmacology in Drug Development|January 8, 2024
Pharmacokinetics, Safety, and Tolerability of a Single 5-Day Treatment of Tirbanibulin Ointment 1% in 100 cm<sup>2</sup> : A Phase 1 Maximal-Use Trial in Patients with Actinic KeratosisJanet DuBois, Terry M Jones, Mark S Lee, et al.
Immunity|August 2, 2015
A Mechanical Switch Couples T Cell Receptor Triggering to the Cytoplasmic Juxtamembrane Regions of CD3ζζMark S Lee, Caleb R Glassman, Neha R Deshpande, et al.
American Journal of Clinical Dermatology|October 29, 2021
Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and PharmacokineticsJohn E Jett, Michael McLaughlin, Mark S Lee, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 31, 2022
Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitisDonald Y M Leung, Amy S Paller, Andrea L Zaenglein, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Immunity|November 22, 2018
Bonds Voyage! A Dissociative Model of TCR-CD3 Triggering Is ProposedKatrina Lichauco, Mark S Lee, Michael S Kuhns
Cell Reports|February 2, 2018
Reciprocal TCR-CD3 and CD4 Engagement of a Nucleating pMHCII Stabilizes a Functional Receptor MacrocomplexCaleb R Glassman, Heather L Parrish, Mark S Lee, et al.
Elife|July 21, 2022
Enhancing and inhibitory motifs regulate CD4 activityMark S Lee, Peter J Tuohy, Caleb Y Kim, et al.
Biorxiv : the Preprint Server for Biology|May 22, 2023
The CD4 transmembrane GGXXG and juxtamembrane (C/F)CV+C motifs mediate pMHCII-specific signaling independently of CD4-LCK interactionsMark S Lee, Peter J Tuohy, Caleb Y Kim, et al.
Elife|April 19, 2024
The CD4 transmembrane GGXXG and juxtamembrane (C/F)CV+C motifs mediate pMHCII-specific signaling independently of CD4-LCK interactionsMark S Lee, Peter J Tuohy, Caleb Y Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2020
A biomimetic five-module chimeric antigen receptor (<sup>5M</sup>CAR) designed to target and eliminate antigen-specific T cellsShio Kobayashi, Martin A Thelin, Heather L Parrish, et al.
Clinical Pharmacology in Drug Development|January 8, 2024
Pharmacokinetics, Safety, and Tolerability of a Single 5-Day Treatment of Tirbanibulin Ointment 1% in 100 cm<sup>2</sup> : A Phase 1 Maximal-Use Trial in Patients with Actinic KeratosisJanet DuBois, Terry M Jones, Mark S Lee, et al.
Immunity|August 2, 2015
A Mechanical Switch Couples T Cell Receptor Triggering to the Cytoplasmic Juxtamembrane Regions of CD3ζζMark S Lee, Caleb R Glassman, Neha R Deshpande, et al.
American Journal of Clinical Dermatology|October 29, 2021
Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and PharmacokineticsJohn E Jett, Michael McLaughlin, Mark S Lee, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 31, 2022
Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitisDonald Y M Leung, Amy S Paller, Andrea L Zaenglein, et al.
Pageof 2